Fiocruz
Brazil's Fiocruz, through its Farmanguinhos unit, has begun fully domestic production of tacrolimus, an immunosuppressant to prevent organ transplant rejection. The milestone stems from a Product Development Partnership (PDP) with Brazilian firm Libbs, which acquired manufacturing technology from India's Biocon. Farmanguinhos now becomes the sole supplier to the SUS public health system.
AI에 의해 보고됨
Pharmaceutical company Gilead Sciences has signed a memorandum of understanding with Farmanguinhos, part of Fiocruz, to assess technology transfer and local production of lenacapavir, a semestral HIV prevention injection. The deal aims to lower costs and improve accessibility in Brazil, though it is not yet a formal commitment. Anvisa approved the drug on January 12, 2026.